Breaking News, Financial News

4Q Financial Reports: GlaxoSmithKline

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline 4Q Revenues: $10.3 billion (+13%) 4Q Earnings: $1.9 billion (+45%) FY Revenues: $37.8 billion (+8%) FY Earnings: $8.2 billion (+20%) Comments: Growth driven by key products: Seretide/Advair, Avandia and the company’s vaccines business. Sales of Seretide/Advair rose 22% to $5.2 billion and sales of Avandia rose 18% to $2.3 billion for the year. The company’s vaccines business posted total sales of $2.4 billion, up 15%, led by Infanrix vaccine. The ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters